Company news

Biogen Inc. news in 2025

Biogen Inc.'s news releases, calls and decks from 2025, newest first.

View company

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

June 29, 2025

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

June 27, 2025

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

June 24, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

June 17, 2025

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

June 17, 2025

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

May 26, 2025

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

April 14, 2025

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

April 1, 2025

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

March 23, 2025

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

March 10, 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 17, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

January 30, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

January 25, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 25, 2025

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

January 22, 2025

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 12, 2025

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

January 9, 2025

← Newer news releases

Calls in 2025

Decks in 2025